MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , |
---|---|
Формат: | Conference item |
Хэл сонгох: | English |
Хэвлэсэн: |
Elsevier
2022
|